Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT02345408 | Phase 1b Study of CCX872-B in Patients With Pancreatic Adenocarcinoma | PHASE1 | COMPLETED | 54 | — | — | Feb 1, 2015 | May 6, 2020 | Feb 27, 2025 | 6 | United States, Netherlands |
| Arm | Type | Description |
|---|---|---|
| CCX872-B | EXPERIMENTAL | 150 mg once or twice daily given orally for at least 12 weeks |
| Name | Type | Description |
|---|---|---|
| CCX872-B | DRUG | Tablets (oral administration) |
Inclusion Criteria: * Histologically or cytologically confirmed non-resectable pancreatic adenocarcinoma with or without metastases * Eastern Cooperative Oncology Group (ECOG) performance status score ≤ 2 * Anticipated life expectancy ≥ 12 weeks * Radiographically measurable disease acc. to RECIST ...